Patent US3611275A successfully refreshed from Google Patents.
Patent US4909251A successfully refreshed from Google Patents.
US4909251A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tissue adhesive
Assignee: IMMUNO AKTIENGESELLSCHAFT A Co OF AUSTRIA
•
Filing: 1989-05-31
•
Granted: 1990-03-20
•
Expires: 2009-05-31
Abstract
Abstract A tissue adhesive in lyophilized form contains at least one biologically compatible tenside beside fibrinogen and factor XIII and optionally further proteins as well as adjuvants or additives. The presence of these biologically compatible tensides was found to shorten the reconstitution times of lyophilized tissue adhesive preparations without negatively affecting the biochemical, mechanical or biological properties of the preparation or of the tibrin formed therefrom.
Inventors
- 👤 Thomas Seelich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 18:09
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; A61L24/001; A61P; A61P43/00; A61P7/00; A61P7/04
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
79 words
In a tissue adhesive for seamlessly or seam-supportingly connecting human or animal tissue or organ parts, for sealing wounds, stopping bleeding and stimulating wound healing in lyophilized form and having a fibrinogen content of at least 0.25 (25% by mass) and a factor XIII content, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen being at least 150, the improvement comprising at least one biologically compatible tenside in addition to fibrinogen.
Claim 2
Dependent Claim
79 words
In a tissue adhesive for seamlessly or seam-supportingly connecting human or animal tissue or organ parts, for sealing wounds, stopping bleeding and stimulating wound healing in lyophilized form and having a fibrinogen content of at least 0.25 (25% by mass) and a factor XIII content, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen being at least 150, the improvement comprising at least one biologically compatible tenside in addition to fibrinogen.
Claim 3
Dependent Claim
45 words
A tissue adhesive as set forth in claim 1, wherein at least one tenside from the group of the non-ionic, cationic, anionic and zwitterionic tensides is present in an amount of from 0.003 to 0.15 (0.03 to 15% by mass) based on the fibrinogen content.
Claim 4
Dependent Claim
27 words
A tissue adhesive as set forth in claim 2, wherein said tenside is present in an amount of from 0.001 to 0.01 (0.1 to 1.0% by mass).
Claim 5
Dependent Claim
40 words
A tissue adhesive as set forth in claim 2, wherein said tissue adhesive contains a tenside selected from the groups of the polyether-alcohols, comprising polyoxyethylene(23)-dodecyl-ether, polyoxyethylene(10)-hexadecyl-ether, polyoxyethylene(20)-hexadecyl-ether, octylphenolpolyethylenglycol(30)-ether, octylphenolpolyethyleneglycol(12-13)-ether, octylphenolpolyethyleneglycol(7-8)-ether, octylphenolpolyethyleneglycol(40)-ether, and octylphenolpolyethyleneglycol-ether-formaldehydepolymers, the polyether esters, or the polyoxyethylene-polyoxypropylene-block polymers.
Claim 6
Dependent Claim
20 words
A tissue adhesive as set forth in claim 4 wherein the tenside is a polyethylene glycol-660-12-hydroxystearate or a polyoxyethylene-stearoyl ester.
Claim 7
Dependent Claim
35 words
A tissue adhesive as set forth in claim 2, wherein said tissue adhesive contains a tenside from the group of the sugar esters, the polyalcohol-anhydride esters, the glycosides, the alkinols, the amine-oxides, or the hydroxyalkyl-amides.
Claim 8
Dependent Claim
24 words
A tissue adhesive as set forth in claim 6 wherein the tenside is sucrose palmitate stearate, sorbitan monolaurate, sorbitan monooleate, octyl-β-D-glucopyranoside, 2,4,7,9-tetramethyl-5-decin-4,7-diol, or docecyl-dimethyl-amineoxide.
Claim 9
Dependent Claim
30 words
A tissue adhesive as set forth in claim 2, wherein said tissue adhesive contains a tenside from the group of the sulfosuccinates, or the alkaline salts of the bile acids.
Claim 10
Dependent Claim
16 words
A tissue adhesive as set forth in claim 8 wherein the tenside is dioctyl-sulfosuccinate or Na-desoxycholate.
Claim 11
Dependent Claim
29 words
A tissue adhesive as set forth in claim 2, wherein said tissue adhesive comprises a tenside from the group of the substituted ammonium salts or of the alkyl-pyridinium salts.
Claim 12
Dependent Claim
20 words
A tissue adhesive as set forth in claim 10 wherein the tenside is benzyldimethyl-2-hydroxyethyl-ammonium chloride, benzy-trimethyl-ammonium chloride, or cetylpyridinium chloride.
Claim 13
Dependent Claim
47 words
A tissue adhesive as set forth in claim 2, wherein said tissue adhesive contains a tenside from the group of the phosphatides, or at least one tenside from the group of the sulfobetains, the zwitterionic bile acid derivatives, the alkylbetains, the sarcosines, or of the imino-dipropanoic acids.
Claim 14
Dependent Claim
22 words
A tissue adhesive as set forth in claim 10 wherein the tenside is lecithin, N-dodecyl-N',N-dimethylammonio-3-propane sulfonate, 3-(3-cholamidopropyl)-dimethylamino-1-propane sulfonate, N-lauroylsarcosine, or N-lauryl-β-imino-dipropanoic acid.
Claim 15
Dependent Claim
82 words
A tissue adhesive as set forth in claim 1, wherein said tissue adhesive is reconstitutable with aqua ad iniectabilia to give a solution ready for use having a concentration of at least 70 mg of fibrinogen/ml, said solution having an osmolarity of 0.70 osmol at the most, said tissue adhesive having an electrolyte content limited such that after a further ten-fold dilution with aqua ad iniectabilia the tissue adhesive has an electric conductivity at 20° C. of 3 mS at the most.
Claim 16
Dependent Claim
58 words
A tissue adhesive in reconstituted form as set forth in claim 14, wherein the fibrin-gamma chains are completely cross-linkable after 3 to 5 minutes and the fibrinalpha chains are cross-linkable to at least 60% after two hours, after mixing with a solution containing thrombin and Ca 2+ ions and incubation at 37° C., determined by sodiumlaurylsulphate-(SDS)-polyacrylamide gel electrophoresis.
Claim 17
Dependent Claim
13 words
A tissue adhesive as set forth in claim 1, further comprising an antoixdant.
Claim 18
Dependent Claim
16 words
A tissue adhesive as set forth in claim 1, further comprising additional substances having antimicrobial activities.
Claim 19
Independent Claim
114 words
A method for seamlessly or seamsupportingly connecting human or animal tissue or organ part, for sealing wounds, stopping bleeding and stimulating wound healing comprising the application of a lyophilized composition based on human or animal proteins comprising a fibrinogen content of at least 0.25 (25% by mass) of the dry substance, a factor XIII content in an amount of at least 150 units per gram of fibrinogen, and a content of at least one biologically compatible tenside, the total tenside content being from 0.0003 to 0.15 (0.03 to 15% by mass) of the fibrinogen content, for producing a tissue adhesive solution ready for use at a concentration of at least 70 mg of fibrinogen/ml.
Claim 20
Independent Claim
114 words
A method for seamlessly or seamsupportingly connecting human or animal tissue or organ part, for sealing wounds, stopping bleeding and stimulating wound healing comprising the application of a lyophilized composition based on human or animal proteins comprising a fibrinogen content of at least 0.25 (25% by mass) of the dry substance, a factor XIII content in an amount of at least 150 units per gram of fibrinogen, and a content of at least one biologically compatible tenside, the total tenside content being from 0.0003 to 0.15 (0.03 to 15% by mass) of the fibrinogen content, for producing a tissue adhesive solution ready for use at a concentration of at least 70 mg of fibrinogen/ml.
Claim 21
Dependent Claim
24 words
The method of claim 18 wherein the composition further comprises a fibronectin content of up to 0.65 (65% by mass) of the fibrinogen content.
Claim 22
Dependent Claim
24 words
The method of claim 18 wherein the composition further comprises an albumin content of up to 1.1 (110% by mass) of the fibrinogen content.
References Cited (Backward Citations)
US4362567A
Cited
US4414976A
Cited
CA1182444A
Cited
US4427650A
Cited
US4427651A
Cited
US4442655A
Cited
CA1168982A
Cited
US4627879A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-19 | 1993-09-18 | 1994-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-19 | 1997-09-18 | 1998-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-19 | 2001-09-18 | 2002-03-20 | $7700.00 | Window Closed / Lapsed |